Can ParC Ser83Ile status predict fluoroquinolone efficacy in Mycoplasma genitalium infection? - Authors' reply
- PMID: 36029779
- DOI: 10.1016/S1473-3099(22)00446-7
Can ParC Ser83Ile status predict fluoroquinolone efficacy in Mycoplasma genitalium infection? - Authors' reply
Conflict of interest statement
All authors receive research funding from SpeeDx, and note that SpeeDx has specific interests related to resistance-guided therapy. SpeeDx had no role in the conception or drafting of this letter.
Comment on
-
Individualised treatment of Mycoplasma genitalium infection-incorporation of fluoroquinolone resistance testing into clinical care.Lancet Infect Dis. 2022 Sep;22(9):e267-e270. doi: 10.1016/S1473-3099(21)00629-0. Epub 2022 Mar 21. Lancet Infect Dis. 2022. PMID: 35325618 Review.
-
Can ParC Ser83Ile status predict fluoroquinolone efficacy in Mycoplasma genitalium infection?Lancet Infect Dis. 2022 Sep;22(9):1273-1274. doi: 10.1016/S1473-3099(22)00450-9. Lancet Infect Dis. 2022. PMID: 36029777 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources